儿童霍奇金淋巴瘤循环肿瘤DNA基因分型研究
本研究对96例儿童霍奇金淋巴瘤患者治疗前循环游离DNA进行靶向测序,72例检出HRS细胞来源变异,变异数与等位基因频率范围分别为1-21个和0.6-42%。治疗前ctDNA量与代谢肿瘤体积相关,且早期评估qPET<3的43例患者ccfDNA中均未检出ctDNA。
要点
- 儿童霍奇金淋巴瘤治疗前ccfDNA可检出HRS细胞来源的基因变异。
- SOCS1变异最常见,9个易位断点中7个涉及SOCS1。
- 早期评估qPET<3患者ccfDNA中ctDNA均不可检出。
核心结论
- 儿童霍奇金淋巴瘤ccfDNA分析适用于确定致病机制和监测治疗反应。
研究设计与样本
- 采用杂交捕获靶向下一代测序分析96例儿童霍奇金淋巴瘤患者治疗前ccfDNA。
主要发现
- 72/96例患者治疗前ccfDNA中检出HRS细胞来源的单核苷酸变异、插入/缺失、易位和VH-DH-JH重排。
- 每例患者变异数为1至21个,等位基因频率为0.6%至42%。
- 检出9个易位断点,其中7个涉及SOCS1;SOCS1变异(主要为缺失)在大多数ctDNA中可见。
- JAK/STAT、NFkB和PI3K信号通路及抗原提呈相关基因最常受累。
- 治疗前ctDNA量与代谢肿瘤体积相关;43例qPET<3患者ccfDNA中均未检出ctDNA,6例qPET>3患者中5例ctDNA仍可检出。
临床怎么用
- ccfDNA靶向测序可用于儿童霍奇金淋巴瘤的致病机制探索和治疗反应监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We used hybrid capture-targeted next-generation sequencing of circulating cell-free DNA (ccfDNA) of pediatric Hodgkin lymphoma (PHL) patients to determine pathogenic mechanisms and assess the clinical utility of this method. Hodgkin-Reed/Sternberg (HRS) cell-derived single nucleotide variants, insertions/deletions, translocations and VH-DH-JH rearrangements were detected in pretherapy ccfDNA of 72 of 96 patients. Number of variants per patient ranged from 1 to 21 with allele frequencies from 0.6 to 42%. Nine translocation breakpoints were detected. Genes involved in JAK/STAT, NFkB and PI3K signaling and antigen presentation were most frequently affected. SOCS1 variants, mainly deletions, were found in most circulating tumor (ct) DNAs, and seven of the nine translocation breakpoints involved SOCS1. Analysis of VH-DH-JH rearrangements revealed an origin of PHL HRS cells from partially selected germinal center B cells. Amounts of pretherapy ctDNA were correlated with metabolic tumor volumes. Furthermore, in all ccfDNA samples of 43 patients with early response assessment quantitative qPET < 3, indicative of a favorable clinical course, ctDNA was not detectable. In contrast, in five of six patients with qPET > 3, indicative of an unfavorable clinical course, ctDNA remained detectable. ccfDNA analysis of PHL is thus a suitable approach to determine pathogenic mechanisms and monitor therapy response.
引用
- Desch AK, Hartung K, Botzen A, et al. Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma. Leukemia. 2019. PMID: 31431735. doi:10.1038/s41375-019-0541-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。